Molecular mechanisms of Myc-induced tumor neovascularization

Myc诱导肿瘤新生血管形成的分子机制

• 批准号: 7392173
• 负责人: Andrei Thomas-Tikhonenko
• 金额: $ 29.93万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2012-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7392173
• 关键词: ABT-510; Address; Adenocarcinoma; Anatomy; Angiogenesis Inhibitors; Angiogenic Switch; Antineoplastic Agents; Antisense Oligonucleotides; Apoptosis; Attenuated; Blood; Blood Vessels; Carcinoma; Cell Proliferation; Cells; Clinical Trials; Colon Adenocarcinoma; Colon Carcinoma; Colorectal Cancer; Complex; Data; Databases; Disease regression; Down-Regulation; Enrollment; Genetic; Goals; Growth; HCT116 Cells; Human; Hypervascular; In Vitro; Indium; Individual; Indolent; KRAS2 gene; Ki-ras Oncogene; Lesion; Malignant Epithelial Cell; Malignant Neoplasms; Mediating; Messenger RNA; MicroRNAs; Modeling; Molecular; Mucous Membrane; Mus; Mutation; Neoplasms; Oligoribonucleotides; Oncogene Proteins; Oncogenes; Patients; Pattern; Peptides; Pharmaceutical Preparations; Phenotype; Principal Investigator; Process; Production; Property; Protein Overexpression; Proteins; Public Health; Regulation; Repression; Research; Research Personnel; Retroviridae; Role; Silicon Dioxide; System; THBS1 gene; TP53 gene; Therapeutic; Therapeutic Effect; Thrombospondin 1; Transcript; Transcriptional Activation; Transgenic Mice; Translations; Tumor Suppressor Proteins; Untranslated Regions; Up-Regulation; Vascular Endothelial Cell; Vascular Endothelial Growth Factors; Xenograft procedure; angiogenesis; base; c-myc Genes; cellular transduction; connective tissue growth factor; in vivo; inhibitor/antagonist; knock-down; mRNA Stability; mRNA Transcript Degradation; member; neoplastic; neovascularization; preclinical study; research study; restoration; small hairpin RNA; therapeutic target; tumor; tumor growth; villin

DESCRIPTION (provided by applicant): The goal of this project is to investigate the molecular mechanisms by which the Myc oncoprotein enhances tumor neovascularization (the ingrowth of blood vessels into the nascent neoplasm). We have developed an experimental system wherein overexpression of this oncoprotein in murine colon carcinoma cells results in the hypervascular phenotype. We determined that this occurs without increased production of vascular endothelial growth factor (VEGF). Instead, Myc down-regulates the potent endogenous inhibitor of angiogenesis thrombospondin-1 and several other members of the TSR superfamily. Thrombospondin-1 is down-regulated primarily at the level of mRNA turnover, suggesting the involvement of microRNAs (miRNAs) which are known to mediate mRNA degradation. Indeed, Myc upregulates one of the miRNA clusters (miR17-92) whose predicted targets include thrombospondin-1 and other TSR proteins. miR17-92 knockdown with antisense 2'-O-methyl oligoribonucleotide partly restores Tsp1 and CTGF expression. Conversely, transduction of Ras-only cells with a miR17-92-encoding retrovirus reduces Tsp1 and CTGF levels. These key findings were also reproduced in HCT116 human colon carcinoma cells. Notably, miR17-92-transduced murine cells form larger, better-perfused tumors. Thus, we have formulated the following overall hypothesis: The contribution of Myc to tumor neovascularization is based on down-regulation of thrombospondin-1 and related proteins via a post-transcriptional mechanism involving the miR17-92 microRNA cluster. To corroborate this hypothesis, we propose to fulfill the following Specific Aims: 1. To dissect the molecular mechanisms underlying downregulation of TSR proteins by the miR17-92 cluster. 2. To establish the significance of Myc-dependent TSR protein down-regulation for neoplastic growth of Myc/Ras colonocytes and human colon cancer xenografts. 3. To elucidate the effects of transient Myc down-regulation on tumor vascularity and overall growth. After having fulfilled these Aims, we will be able to commence large-scale pre-clinical studies further validating miR17-92 and Myc as non-cell-autonomous therapeutic targets in vivo. RELEVANCE TO PUBLIC HEALTH: One of the promising anti-cancer drugs currently undergoing clinical trials is ABT-510. This drug mimics the effects of the natural tumor suppressor thrombospondin. Our research will help determine what types of colorectal cancer might be particularly sensitive to ABT-510 and allow for targeted patient enrollment. Additionally, our studies identify certain microRNAs as potential targets for anti-angiogenic therapies.

项目描述（由申请人提供）：该项目的目标是研究Myc癌蛋白促进肿瘤新生血管形成（血管向新生肿瘤内生长）的分子机制。我们已经开发了一种实验系统，其中在小鼠结肠癌细胞中过度表达这种癌蛋白会导致高血管表型。我们确定这种情况不会增加血管内皮生长因子（VEGF）的产生。相反，Myc下调血管生成血栓反应蛋白-1的内源性抑制剂和TSR超家族的其他几个成员。血小板反应蛋白-1主要在mRNA转换水平下调，表明已知介导mRNA降解的microrna （mirna）参与其中。事实上，Myc上调了其中一个miRNA簇（miR17-92），其预测靶点包括血栓反应蛋白1和其他TSR蛋白。用反义2'- o -甲基寡核苷酸敲除miR17-92部分恢复Tsp1和CTGF的表达。相反，用mir17 -92编码逆转录病毒转导Ras-only细胞可降低Tsp1和CTGF水平。这些关键发现也在HCT116人结肠癌细胞中重现。值得注意的是，mir17 -92转导的小鼠细胞形成更大、灌注更好的肿瘤。因此，我们提出了以下总体假设：Myc对肿瘤新生血管的贡献是基于通过涉及miR17-92 microRNA簇的转录后机制下调血栓反应蛋白1和相关蛋白。为了证实这一假设，我们提出实现以下具体目标：1。剖析miR17-92簇下调TSR蛋白的分子机制。2. 目的：探讨Myc依赖性TSR蛋白下调对Myc/Ras结肠细胞和人结肠癌异种移植物肿瘤生长的影响。3. 目的：探讨瞬时Myc下调对肿瘤血管和整体生长的影响。在完成这些目标后，我们将能够开始大规模的临床前研究，进一步验证miR17-92和Myc作为体内非细胞自主治疗靶点。与公共卫生相关：ABT-510是目前正在进行临床试验的一种很有前景的抗癌药物。这种药物模拟天然肿瘤抑制剂血栓反应蛋白的作用。我们的研究将有助于确定哪种类型的结直肠癌可能对ABT-510特别敏感，并允许有针对性的患者登记。此外，我们的研究确定了某些microrna作为抗血管生成治疗的潜在靶点。